Genetix
Biotech eyes academics R&D
Molecular biology and
cell culture have been the strength of Genetix Biotech last year,
it derives majority of its revenues from the biopharma
industry but is now looking at leveraging its business from academia.
![](/IMG/161/45161/11rank.gif)
Delhi-based Genetix Biotech Asia represents
market leaders in biotechnology/life sciences, laboratory research
products such as filtration membranes and devices, molecular biology
kits and reagents, biochemistry, protein assays, fine chemicals,
immunology reagents, cell and tissue culture, serum and media,
chromatography accessories and various instruments for leading
multinational brands.
The company registered an approximate growth of 14 percent in the
fiscal 2008-09 with revenues of Rs 80 crore up from Rs 70 crore last
year. It registered a growth of 42 percent over last year. The company
has been growing at an average rate of 30-40 percent for the last
several years. The company derives almost 55 percent of its revenues
from the biopharmaceutical industry (both R&D and production)
with companies such as Reliance Life Sciences, Serum Institute of
India, Indian Immunologicals and Shantha Biotech as its clients. About
45 percent of its revenues are derived from the research segment and
five percent from diagnostics. Last year has been tough for the company
with several factors that prompted industry players to restrain
business including recession in the global market.
Talking about the growth drivers, Arun Prakash, CEO, Genetix Biotech
Asia, said, “The company added three new principals to its
portfolio including-Ashnon & Corbett research. Molecular and
cell biology and culture business has been our strength both from
industry and research point of view. Molecular biology research
products from Qiagen and Fermentas have been the best selling
products.”
The fiscal 2007-08 saw Stratagene (microbiology) and HyClone
(cell culture and bioproduction), two prominent principals return to
Genetix with Hyclone contributing close to around 12 crore of the total
revenues. A whole range of bioseparation products including filtration,
chromatography, ultrafiltration under the Genetix brand was also
launched. The company is also working on a project under SIBRI worth Rs
80 lakh sanctioned by DBT in the area of developing molecular
diagnostics for two bovine diseases. It also has a full-fledged
molecular biology and cell culture laboratory for in-house training,
customer demonstration/training and quality control back up.
“We have changed our focus from being completely on the
industry and focusing on academics R&D. We shall be also
getting into manufacturing of various products as well and have plans
lined up for that,” added Arun Prakash.